Voyager, AbbVie partner for AD gene therapies

Gene therapy company Voyager Therapeutics Inc. (NASDAQ:VYGR) jumped $4.30 (22%) to $23.66 on Tuesday after partnering with AbbVie Inc. (NYSE:ABBV) to develop gene therapies to express microtubule-associated protein tau (tau; MAPT;

Read the full 310 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE